Loading...
•
Dec 31, 2019
Leap Therapeutics Q4 2019 Earnings Report
Reported financial results for the fourth quarter and year ended December 31, 2019.
Key Takeaways
Leap Therapeutics reported its Q4 2019 financial results, noting a decrease in research and development expenses due to reduced clinical trial costs and lower manufacturing and consulting expenses. The company highlighted progress in the clinical development of DKN-01 and securing a strategic partnership with BeiGene.
DKN-01 has shown activity against multiple difficult-to-treat tumor types.
A strategic partnership was secured with BeiGene for DKN-01 development in the Asia-Pacific region.
Clinical trials combining DKN-01 with BeiGene’s anti-PD-1 antibody, tislelizumab, are expected to begin in the first half of 2020.
The Society of Gynecologic Oncology's 2020 Annual Meeting on Women’s Cancer was canceled due to COVID-19.